Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
- Status
- TERMINATED
- Phase
- PHASE2
Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
- Status
- TERMINATED
- Phase
- PHASE3
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
MEmbranous Nephropathy Trial Of Rituximab
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- N/A
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
- Status
- TERMINATED
- Phase
- PHASE2
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Rituximab to Prevent Recurrence of Proteinuria
- Status
- TERMINATED
- Phase
- PHASE3
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
- Status
- COMPLETED
- Phase
- PHASE2
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
- Status
- TERMINATED
- Phase
- PHASE2
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
- Status
- COMPLETED
- Phase
- PHASE2